Retatrutide (LY3437943) is an investigational triple receptor agonist studied at the GIP, GLP-1 and glucagon receptors. Published phase 2 work and later reviews describe the mechanism, while long term outcome data is not available. Material supplied by Vitality Peps is for in vitro laboratory research only.
For research purposes only. Not for human consumption. This article is educational and references published laboratory research; it is not medical advice and does not describe an approved use of any compound.
Retatrutide (LY3437943) is an investigational triple receptor agonist that has drawn substantial attention in metabolic research literature. This overview summarises what published work describes, how the compound is handled in a laboratory setting, and where the evidence currently stops.
What retatrutide is
Retatrutide is a synthetic peptide described in the literature as a single molecule with agonist activity at three receptors: GIP, GLP-1 and glucagon. That triple profile is why it is often referred to informally as a GLP-3 or triple G compound. It is structurally distinct from dual agonists such as tirzepatide, which act at GIP and GLP-1 only.
The compound is investigational. It has not completed the regulatory approval process in the European Union or elsewhere, and no marketing authorisation exists for it. Everything below describes published research, not an approved use.
Why the triple mechanism is studied
Published phase 2 work reported in the New England Journal of Medicine characterises the pharmacodynamic profile of the molecule across the three receptor targets. The research interest lies in whether simultaneous activity at glucagon alongside the two incretin receptors produces a different metabolic signature than incretin activity alone.
Because the compound is still under investigation, the literature is best read as characterising a mechanism rather than establishing an outcome. Reviews published since 2023 consistently note that long term data is not yet available.
Handling in a research setting
Retatrutide is supplied lyophilised. Standard laboratory handling for a lyophilised peptide applies:
- Store the sealed vial refrigerated and shielded from light, as set out in the storage guide. Frozen storage is used for longer holds.
- Allow the vial to reach room temperature before reconstitution to limit condensation inside the vial.
- Reconstitute with bacteriostatic water, directing the stream against the vial wall rather than onto the powder.
- Do not shake. Swirl gently until the solution is clear.
- Record batch number and reconstitution date. Reconstituted peptide is a time limited preparation.
Common questions in the literature
Storage duration after reconstitution: the general laboratory convention for bacteriostatic water preparations is refrigerated storage measured in weeks rather than months, with the exact window depending on the peptide and the diluent used.
Comparison with dual agonists: the distinguishing variable in the published work is glucagon receptor activity. Any comparison beyond receptor binding is not currently supported by head to head data.
Concentration: this is a calculation, not a recommendation. Our reconstitution calculator converts vial mass and diluent volume into a concentration and a syringe mark for research measurement.
Regulatory and research use status
Retatrutide sold by Vitality Peps is supplied strictly for in vitro laboratory research. It is not a medicine, not a supplement, and not for human or veterinary consumption. Nothing in this article should be read as guidance for use in humans.
Frequently asked questions
What makes retatrutide different from a dual agonist?
The published distinction is glucagon receptor activity alongside GIP and GLP-1. Dual agonists act at two of those receptors only, so any comparison beyond receptor binding is not supported by head to head data.
Is retatrutide approved anywhere?
No. It is investigational and holds no marketing authorisation in the European Union or elsewhere. It is supplied here strictly as a research compound.
How is the lyophilised vial handled in a laboratory?
Sealed vials are kept refrigerated and shielded from light, brought to room temperature before reconstitution, and reconstituted with bacteriostatic water without shaking. The storage guide sets out the full handling routine.
Where does the published evidence currently stop?
Reviews published since 2023 consistently note that the literature characterises a mechanism rather than establishing long term outcomes.
For research purposes only. Not for human consumption. This article is educational and references published laboratory research; it is not medical advice and does not describe an approved use of any compound.